<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82321AD2-CD2E-456C-9395-59CF155A3EC8"><gtr:id>82321AD2-CD2E-456C-9395-59CF155A3EC8</gtr:id><gtr:name>Sanofi</gtr:name><gtr:address><gtr:line1>174 avenue de France</gtr:line1><gtr:line4>Paris cedex 13</gtr:line4><gtr:postCode>75635</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/72F4A4EA-BEBF-47BB-AC75-CD8157D7B17C"><gtr:id>72F4A4EA-BEBF-47BB-AC75-CD8157D7B17C</gtr:id><gtr:name>Tata Memorial Hospital</gtr:name><gtr:address><gtr:line1>Cancer Research Centre</gtr:line1><gtr:line2>Dr. E Borges Road</gtr:line2><gtr:postCode>400 012</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9FE0E616-6A75-4DCC-BA07-3ADF018A9669"><gtr:id>9FE0E616-6A75-4DCC-BA07-3ADF018A9669</gtr:id><gtr:name>National Cancer Research Institute</gtr:name><gtr:address><gtr:line1>National Cancer Research Institute</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/50D230BC-805B-45A1-81B6-BA53637AC613"><gtr:id>50D230BC-805B-45A1-81B6-BA53637AC613</gtr:id><gtr:name>Irish Clinical Oncology Research Group (ICORG)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/727DAA84-5778-46E5-AD06-516799EFA403"><gtr:id>727DAA84-5778-46E5-AD06-516799EFA403</gtr:id><gtr:name>Almac Group</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8E329B6D-2452-4161-AE92-B21E9D8AF75A"><gtr:id>8E329B6D-2452-4161-AE92-B21E9D8AF75A</gtr:id><gtr:name>Immatics Biotechnologies GmbH</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7035AE5D-F006-4762-9959-D965363291F6"><gtr:id>7035AE5D-F006-4762-9959-D965363291F6</gtr:id><gtr:name>Merck</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/33E5EB17-8A9B-43F4-AA33-1FBF483ECEE2"><gtr:id>33E5EB17-8A9B-43F4-AA33-1FBF483ECEE2</gtr:id><gtr:name>Baxter</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AF8E5862-E5CC-41F8-A6E5-56EB00D97CE1"><gtr:id>AF8E5862-E5CC-41F8-A6E5-56EB00D97CE1</gtr:id><gtr:name>ARCAD Foundation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1CC23DC2-3991-4123-B5F2-83C1F5793403"><gtr:id>1CC23DC2-3991-4123-B5F2-83C1F5793403</gtr:id><gtr:name>F. Hoffmann-La Roche AG</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DD698BE9-1ED7-42BF-AC5D-427A5CA5851D"><gtr:id>DD698BE9-1ED7-42BF-AC5D-427A5CA5851D</gtr:id><gtr:name>Bayer</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/666A7C6D-E59C-4C37-8997-490B93914C41"><gtr:id>666A7C6D-E59C-4C37-8997-490B93914C41</gtr:id><gtr:name>MRC Clinical Trials Unit</gtr:name><gtr:address><gtr:line1>Aviation House</gtr:line1><gtr:line2>125 Kingsway</gtr:line2><gtr:postCode>WC2B 6NH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/666A7C6D-E59C-4C37-8997-490B93914C41"><gtr:id>666A7C6D-E59C-4C37-8997-490B93914C41</gtr:id><gtr:name>MRC Clinical Trials Unit</gtr:name><gtr:address><gtr:line1>Aviation House</gtr:line1><gtr:line2>125 Kingsway</gtr:line2><gtr:postCode>WC2B 6NH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82321AD2-CD2E-456C-9395-59CF155A3EC8"><gtr:id>82321AD2-CD2E-456C-9395-59CF155A3EC8</gtr:id><gtr:name>Sanofi</gtr:name><gtr:address><gtr:line1>174 avenue de France</gtr:line1><gtr:line4>Paris cedex 13</gtr:line4><gtr:postCode>75635</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/72F4A4EA-BEBF-47BB-AC75-CD8157D7B17C"><gtr:id>72F4A4EA-BEBF-47BB-AC75-CD8157D7B17C</gtr:id><gtr:name>Tata Memorial Hospital</gtr:name><gtr:address><gtr:line1>Cancer Research Centre</gtr:line1><gtr:line2>Dr. E Borges Road</gtr:line2><gtr:postCode>400 012</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9FE0E616-6A75-4DCC-BA07-3ADF018A9669"><gtr:id>9FE0E616-6A75-4DCC-BA07-3ADF018A9669</gtr:id><gtr:name>National Cancer Research Institute</gtr:name><gtr:address><gtr:line1>National Cancer Research Institute</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/50D230BC-805B-45A1-81B6-BA53637AC613"><gtr:id>50D230BC-805B-45A1-81B6-BA53637AC613</gtr:id><gtr:name>Irish Clinical Oncology Research Group (ICORG)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/727DAA84-5778-46E5-AD06-516799EFA403"><gtr:id>727DAA84-5778-46E5-AD06-516799EFA403</gtr:id><gtr:name>Almac Group</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8E329B6D-2452-4161-AE92-B21E9D8AF75A"><gtr:id>8E329B6D-2452-4161-AE92-B21E9D8AF75A</gtr:id><gtr:name>Immatics Biotechnologies GmbH</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7035AE5D-F006-4762-9959-D965363291F6"><gtr:id>7035AE5D-F006-4762-9959-D965363291F6</gtr:id><gtr:name>Merck</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/33E5EB17-8A9B-43F4-AA33-1FBF483ECEE2"><gtr:id>33E5EB17-8A9B-43F4-AA33-1FBF483ECEE2</gtr:id><gtr:name>Baxter</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AF8E5862-E5CC-41F8-A6E5-56EB00D97CE1"><gtr:id>AF8E5862-E5CC-41F8-A6E5-56EB00D97CE1</gtr:id><gtr:name>ARCAD Foundation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1CC23DC2-3991-4123-B5F2-83C1F5793403"><gtr:id>1CC23DC2-3991-4123-B5F2-83C1F5793403</gtr:id><gtr:name>F. Hoffmann-La Roche AG</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DD698BE9-1ED7-42BF-AC5D-427A5CA5851D"><gtr:id>DD698BE9-1ED7-42BF-AC5D-427A5CA5851D</gtr:id><gtr:name>Bayer</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/1FFD79A0-0681-4141-A504-FDE130EF7F33"><gtr:id>1FFD79A0-0681-4141-A504-FDE130EF7F33</gtr:id><gtr:firstName>Mahesh</gtr:firstName><gtr:surname>Parmar</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3591B22B-5D64-4E64-88AB-6FF834EBF6BF"><gtr:id>3591B22B-5D64-4E64-88AB-6FF834EBF6BF</gtr:id><gtr:firstName>Ruth</gtr:firstName><gtr:otherNames>Elizabeth</gtr:otherNames><gtr:surname>Langley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9A9F0306-4D6C-4FA0-9A03-92A30F32ACD9"><gtr:id>9A9F0306-4D6C-4FA0-9A03-92A30F32ACD9</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Stephens</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BBA2E631-E32F-4AF1-BC17-ED665661D718"><gtr:id>BBA2E631-E32F-4AF1-BC17-ED665661D718</gtr:id><gtr:firstName>Angela</gtr:firstName><gtr:otherNames>M</gtr:otherNames><gtr:surname>Meade</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0C59F358-7424-439C-BECF-3CF953EA65F3"><gtr:id>0C59F358-7424-439C-BECF-3CF953EA65F3</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:surname>Kaplan</gtr:surname><gtr:orcidId>0000-0002-0189-8348</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U122861325"><gtr:id>6012539A-4B14-4219-B7B6-CA7F42A2B575</gtr:id><gtr:title>Clinical trials in colorectal cancer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U122861325</gtr:grantReference><gtr:abstractText>The MRC-CTU colorectal team co-ordinate large controlled clinical trials aimed at progressively improving treatment outcomes in advanced colorectal cancer and early rectal cancer.||Four trials have tested chemotherapy and biological therapies in patients with advanced colorectal cancers. These are quite frequent tumours, but there have been major improvements, chemotherapy having increased survival from about 6 months to 10-12 months, and to between 16 20 months with addition of new agents. The COIN trial explores the addition of newer selective biological therapies hoping to further improve patients chances of living longer. COIN also tests the effectiveness of intermittent combination chemotherapy (giving patients holidays off chemotherapy). The COIN-B trial will provide further information on safety and effectiveness of adding biologics to intermittent chemotherapy. FOCUS3 is an initial test of molecular treatment selection based on characteristics of individual patients tumours. This is potentially a critical step in individualising therapy, selecting best options for each person and minimising use of agents that are unlikely to benefit him/her.||The team have also completed an important trial in early rectal cancer, which are likely to change the way patients with rectal cancer are treated both in the UK and worldwide by showing that the addition of a short course of radiotherapy prior to surgery results in a reduction in the likelihood of a rectal cancer returning.</gtr:abstractText><gtr:technicalSummary>Colorectal cancer is the second most common site of cancer, with around 1 million cases diagnosed each year worldwide, accounting for about 9% of all new cancer cases. In the UK around 35,000 people are diagnosed with the disease, and 16,000 patients die each year (CR-UK Cancer Stats 2003). Most patients die of advanced disease. The colorectal team continues to run a series of large multicentre randomised trials, mainly aimed at optimising the treatment of patients with advanced disease. The team also manage follow-up of a trial in rectal cancer which completed accrual in 2005. FOCUS (CR08) commenced in May 2000 and recruited 2,135 patients by December 2003. The trial was a 5-arm randomised trial comparing the use of irinotecan and oxaliplatin in combination with 5FU either given as first-line treatment or held in reserve as second-line treatment after the failure of 5FU alone. The control arm was the UK standard treatment of 5FU followed on progression by single-agent irinotecan. All four of the research arms gave longer overall survival than the control arm. Most of the differences did not reach the predetermined 1% significance level for superiority, the comparison between the first-line combination of Irinotecan and 5FU and the control arm was the most promising (HR 0.84 (0.73-0.96; p=0.01)). The main results from the trial were published in the Lancet in 2007 (Seymour et al., Lancet 2007; 370:143-152.). Furthermore, all patients in FOCUS were asked at the time of randomisation for consent to retrieve surplus stored pathology material for molecular study. Thus FOCUS provided an excellent resource for studying the relationship between molecular variables and treatment effect. Preliminary results were presented at the American Society of Clinical Oncology (ASCO) annual meetings in 2004 and 2006. Several papers on this work have been published, while another was recently submitted for publication. This tumour tissue resource has been further expanded in the sequence of trials that followed and represents an increasingly valuable asset for biomarker and translational research. FOCUS2 (CR09) opened in January 2004 and closed in July 2006 following the recruitment of 459 patients. FOCUS2 was designed to assess lower-dose treatment for patients with advanced colorectal cancer who were ineligible or unsuitable for trials of full-dose combination chemotherapy because of poor general health status, advanced age or both. Patients were randomised in a 2x2 fashion to receive one of the four following chemotherapy treatment plans: 1st-line: 5FU/FA (MdG) 1st-line: capecitabine (Cap) 2nd-line: Oxaliplatin(Ox)MdG 2nd-line: OxMdG 1st-line: OxMdG 1st-line: OxCap Chemotherapy was started at 80% of standard dose with the option of increasing to 100% at 6 weeks if well-tolerated. The principal outcome measures were progression free survival for the addition of oxaliplatin (Ox) comparison and quality of life for the MdG/Capecitabine (Cap) comparison. Preliminary results have been presented in the form of a poster presentation at ASCO 2007 and the National Cancer Research Institute (NCRI) meeting in 2007. An oral presentation was given at the European CanCer Organisation (ECCO) meeting in 2007. Ox containing regimens showed a slightly longer progression free survival (PFS) however, these differences did not reach the pre-defined significance level of 5%. The addition of Ox did show an improvement in patients reported quality of life (QL) at 12 weeks (62% vs. 49%, p=0.04). There was no impact on the overall survival (OS) despite the significantly improved response rates (15% vs. 41%, p&amp;lt;0.001). There was some evidence that the addition of oxaliplatin reduced the ability to dose increase at the 6 week time point despite there being no difference in the grade 33 toxicity rates. The substitution of MdG with Cap had no effect on PFS, OS or the QL at 12 weeks, however there was a statistically significant increase in overall grade 33 toxicity (2</gtr:technicalSummary><gtr:fund><gtr:end>2013-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1998-10-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>6611838</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen's University Belfast</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>S-CORT MRC-CRUK Consortium</gtr:description><gtr:id>71998E60-8582-412A-9422-C62E972812AD</gtr:id><gtr:impact>Some preliminary publications, but main outputs are yet to come</gtr:impact><gtr:outcomeId>56dc26f83d1999.27596844-3</gtr:outcomeId><gtr:partnerContribution>The development of a portal for entry and curation of large scale biological data (Oxford); the performance of translational laboratory studies (all the other partners)</gtr:partnerContribution><gtr:piContribution>We serve as the central link between the clinical and outcome data of thousands of patients, access to their tumour and blood samples, and the data from an array of translational laboratory studies carried out by the consortium as a whole. We also provide statistical design advice.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Merck</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>COIN Merck Collaboration</gtr:description><gtr:id>2CC56AC5-DBCF-4BF4-A39B-C4D0D28AEC74</gtr:id><gtr:impact>The COIN trial recently completed accrual and the first results were presented at the ESMO/ECCO international congress in Sept 2009 and at the NCRI annual meeting in October 2009. Manuscripts describing the trials and the results are in preparation. One publication has also resulted from this trial to date: PMID 19165196. Main results have been submitted for publication in 3 manuscripts.</gtr:impact><gtr:outcomeId>5AC254546D9-1</gtr:outcomeId><gtr:partnerContribution>Merck have provided free cetuximab for use in the MRC COIN and COIN-B trials and will provide free cetuximab for the future FOCUS-3 feasibility trial</gtr:partnerContribution><gtr:piContribution>MRC CTU have been responsible for the design, co-ordination, management and analysis of the MRC COIN and COIN-B trials.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Research Institute (NCRI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>National Cancer Research Network (NCRN)</gtr:department><gtr:description>Colorectal Trial Collaborators - Participating Sites</gtr:description><gtr:id>B73C4ACC-C629-47AA-A144-054938FD3D34</gtr:id><gtr:impact>Results from the MRC CR07 trial have been presented at national and international scientific meetings. Primary trial publications: 19269519 and 19269520 Results from the MRC FOCUS trial have been presented at national and international scientific meetings. Primary trial publication: 17630037 Results from the MRC FOCUS2 trial have been presented at national and international scientific meetings. A manuscript presenting the trial results is currently in preparation. The COIN trial completed accrual, was presented at the ESMO/ECCO international congress in Sept 2009 and at the NCRI annual meeting in October 2009 and was published by a pair of reports in Lancet and Lancet Oncology. A manuscript describing the outcome of FOCUS-3 is in preparation. 
In addition, a comprehensive colorectal specimen bank was developed from the COIN, COIN-B, and FOCUS-3 trials (and will also involve specimens from FOCUS4). From this repository a large number of translational projects have been launched and several have now been published (see references).</gtr:impact><gtr:outcomeId>6808DE5FB9D-1</gtr:outcomeId><gtr:partnerContribution>This collaboration includes research staff at each of the roughly 120 clinical sites that have participated in the colorectal clinical trials. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.</gtr:partnerContribution><gtr:piContribution>MRC CTU have been responsible for the design, co-ordination, management and analysis of the MRC CR07 (1350 patients), FOCUS (2135 patients), FOCUS-2 (460 patients), COIN (2445 patients) and COIN-B (target 158 patients with KRAS wild-type tumours) trials. Subsequently, the MRC-funded pilot FOCUS-3 trial was completed and the massive, co-funded (EME + CRUK) molecularly stratified FOCUS4 trial is set to launch in Dec 2013.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Wellcome Trust Sanger Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>S-CORT MRC-CRUK Consortium</gtr:description><gtr:id>3F784BFA-DD7E-4EE9-BC2F-B63928F792FE</gtr:id><gtr:impact>Some preliminary publications, but main outputs are yet to come</gtr:impact><gtr:outcomeId>56dc26f83d1999.27596844-4</gtr:outcomeId><gtr:partnerContribution>The development of a portal for entry and curation of large scale biological data (Oxford); the performance of translational laboratory studies (all the other partners)</gtr:partnerContribution><gtr:piContribution>We serve as the central link between the clinical and outcome data of thousands of patients, access to their tumour and blood samples, and the data from an array of translational laboratory studies carried out by the consortium as a whole. We also provide statistical design advice.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen's University Belfast</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Cancer Research and Cell Biology</gtr:department><gtr:description>Colorectal Trials - Queen's University</gtr:description><gtr:id>19251BEA-E40E-47A2-A084-2A320FC25108</gtr:id><gtr:impact>No outputs to date.</gtr:impact><gtr:outcomeId>UCM2cZwE7nA-1</gtr:outcomeId><gtr:partnerContribution>This QUB team will investigate the significance of the pro-angiogenic CXC-chemokine interleukin-8 (IL-8) within the tumour microenvironment of CRC in modulating the response to FOLFOX chemotherapy.</gtr:partnerContribution><gtr:piContribution>MRC have provided tumour samples from patients enrolled in the MRC COIN/COIN-B trials together with some clinical data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>ARCAD Foundation</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>ARCAD Database Project</gtr:description><gtr:id>B5B2D2BA-B68B-4DDC-BCC2-DF60E4A24F6D</gtr:id><gtr:impact>pending</gtr:impact><gtr:outcomeId>oh8bwdxYqCT-1</gtr:outcomeId><gtr:partnerContribution>Jointly investigating the utility and validity of intermediate endpoints such as PFS to longer term endpoints, particularly overall survival</gtr:partnerContribution><gtr:piContribution>Data from FOCUS and COIN, and ultimately other colorectal trials contributing to large multi-national, multi-trial, database in which non-trioal specific questions can be explored</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leeds</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>S-CORT MRC-CRUK Consortium</gtr:description><gtr:id>2092DA68-87D7-4ECD-B6D2-89EB69311AB9</gtr:id><gtr:impact>Some preliminary publications, but main outputs are yet to come</gtr:impact><gtr:outcomeId>56dc26f83d1999.27596844-5</gtr:outcomeId><gtr:partnerContribution>The development of a portal for entry and curation of large scale biological data (Oxford); the performance of translational laboratory studies (all the other partners)</gtr:partnerContribution><gtr:piContribution>We serve as the central link between the clinical and outcome data of thousands of patients, access to their tumour and blood samples, and the data from an array of translational laboratory studies carried out by the consortium as a whole. We also provide statistical design advice.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Research Institute (NCRI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>National Cancer Research Network (NCRN)</gtr:department><gtr:description>Colorectal trials - NCRN</gtr:description><gtr:id>E6E7A4E8-FDE3-42BB-9657-AA1E2EBF7E88</gtr:id><gtr:impact>Results from the MRC CR07 trial have been presented at national and international scientific meetings. Primary trial publications: 19269519 and 19269520 Results from the MRC FOCUS trial have been presented at national and international scientific meetings. Primary trial publication: 17630037 Results from the MRC FOCUS2 trial have been presented at national and international scientific meetings. A manuscript presenting the trial results is currently in preparation. The COIN trial recently completed accrual and the first results were presented at the ESMO/ECCO international congress in Sept 2009 and at the NCRI annual meeting in October 2009. Manuscripts describing the trials and the results are in preparation. One publication has also resulted from this trial to date: PMID 19165196. Main trial results have been submitted for publication in 3 manuscripts.</gtr:impact><gtr:outcomeId>E2D29F7A4FE-1</gtr:outcomeId><gtr:partnerContribution>The NCRN (a component of NIHR and funded by the English Dept of Health) and corresponding networks in the other UK nations provide the infrastructure in which the trial was run at participating hospitals. In particular, it supports local research nurses and data managers who are responsible for collecting and returning trial data to the CTU.</gtr:partnerContribution><gtr:piContribution>MRC CTU have been responsible for the design, co-ordination, management and analysis of the MRC CR07, FOCUS , FOCUS-2, COIN and COIN-B trials.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>CRUK/MRC Oxford Institute for Radiation Oncology</gtr:department><gtr:description>Oxford University</gtr:description><gtr:id>F47CF837-244F-4E1B-AC02-0CABF375984F</gtr:id><gtr:impact>none yet</gtr:impact><gtr:outcomeId>XEDFGc8GcLz-1</gtr:outcomeId><gtr:partnerContribution>Hosting CI and one or more research fellows in support of major new colorectal cancer trial</gtr:partnerContribution><gtr:piContribution>Major collaboration in developing, and jointly applying for funding for a stratified medicine trial</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Collaboration with GSK and Novartis for FOCUS4</gtr:description><gtr:id>A396709B-2D12-4D69-B5F2-1D78868006B8</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>F5phUuxFfHn-2</gtr:outcomeId><gtr:partnerContribution>Planned supply of agents, placebos and costs of distribution to multiple participating sites, + modest additional financial support to the overall trial</gtr:partnerContribution><gtr:piContribution>Provision of the FOCUS4 trial as a framework for investigation of multiple GSK agents, and combinations, in defined molecular subtypes of colorectal cancer. The original arrangement is being modified to accommodate the agreements between GSK and Novartis relevant to their portfolio of oncology products.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sanofi</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Aventis</gtr:department><gtr:description>FOCUS Aventis Collaboration</gtr:description><gtr:id>F4BB32BB-49C5-4FEC-B070-39A60628D6C7</gtr:id><gtr:impact>Results from the MRC FOCUS trial have been presented at national and international scientific meetings. Primary trial publication: 17630037</gtr:impact><gtr:outcomeId>F73FCABB8DF-1</gtr:outcomeId><gtr:partnerContribution>Sanofi-Synthelabo provided free oxaliplatin for patients in Arm E of the MRC FOCUS trial</gtr:partnerContribution><gtr:piContribution>MRC CTU have been responsible for the design, co-ordination, management and analysis of the MRC FOCUS trial.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Collaboration with GSK and Novartis for FOCUS4</gtr:description><gtr:id>C19B37A5-CE2F-4CB5-A33E-D0169BBD7EB3</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>F5phUuxFfHn-1</gtr:outcomeId><gtr:partnerContribution>Planned supply of agents, placebos and costs of distribution to multiple participating sites, + modest additional financial support to the overall trial</gtr:partnerContribution><gtr:piContribution>Provision of the FOCUS4 trial as a framework for investigation of multiple GSK agents, and combinations, in defined molecular subtypes of colorectal cancer. The original arrangement is being modified to accommodate the agreements between GSK and Novartis relevant to their portfolio of oncology products.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Irish Clinical Oncology Research Group (ICORG)</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:description>COIN-ICORG</gtr:description><gtr:id>D1D8F694-222D-4336-92C5-AA1DC82DE53D</gtr:id><gtr:impact>The COIN trial recently completed accrual and the first results were presented at the ESMO/ECCO international congress in Sept 2009 and at the NCRI annual meeting in October 2009. Manuscripts describing the trials and the results are in preparation. One publication has also resulted from this trial to date: PMID 19165196</gtr:impact><gtr:outcomeId>B10F9370286-1</gtr:outcomeId><gtr:partnerContribution>ICORG co-ordinated the participation of 10 sites in the Republic of Ireland in the COIN trial; 49 patients were recruited from these 10 sites.</gtr:partnerContribution><gtr:piContribution>MRC CTU have been responsible for the design, co-ordination, management and analysis of the MRC COIN trial.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tata Memorial Hospital</gtr:collaboratingOrganisation><gtr:country>India, Republic of</gtr:country><gtr:description>Add-Aspirin - Tata Memorial Hospital</gtr:description><gtr:id>144DA573-F7F6-4674-A950-67F5656683E6</gtr:id><gtr:impact>In terms of the Add-Aspirin trial, the collaboration will speed up delivery of the research and enable demonstration of the health intervention in a range of settings, increasing the potential global impact of the results. Additionally, the work is facilitating development of a cancer research network in India and will pave the way for future collaborative projects.</gtr:impact><gtr:outcomeId>5459f8d38b2a80.40216637-1</gtr:outcomeId><gtr:partnerContribution>Management and oversight of the Add-Aspirin trial in India.</gtr:partnerContribution><gtr:piContribution>Leading the Add-Aspirin trial; management of the trial in the UK; oversight and mentoring of the research group at the Tata Memorial Hospital who will manage Indian participation in the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Colorectal trials Pfizer</gtr:description><gtr:id>98F0F678-1B1E-4EB6-9010-09488D69903C</gtr:id><gtr:impact>FOCUS3 trial initiated and FOCUS 4 trial in planning stages</gtr:impact><gtr:outcomeId>THZGJDuY31a-1</gtr:outcomeId><gtr:piContribution>Developing new colorectal cancer trials that incorporate molecular stratification on the basis of putative biomarker predictors of response.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leeds</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Medicine and Health</gtr:department><gtr:description>Colorectal Trials - University of Leeds</gtr:description><gtr:id>665F3BF7-AD7C-40E1-8FED-BC9688A8B0C5</gtr:id><gtr:impact>Results from the translational studies associated with the FOCUS and FOCUS-2 trials have been presented at national and international scientific meetings. PMID references: 18509181, 19884549 and 19858398 The translational research associated with the CR07 and FOCUS3 trials is due to begin in 2010.</gtr:impact><gtr:outcomeId>88608B22571-1</gtr:outcomeId><gtr:partnerContribution>The translational research components of the MRC CR07, FOCUS, FOCUS-2 trials and part of the translational research component of the FOCUS-3 trial were carried out or are currently being carried out by research teams at the University of Leeds</gtr:partnerContribution><gtr:piContribution>The colorectal team at the MRC CTU work closely with the translational research teams at the University of Leeds to ensure the success of the translational studies attached to the colorectal clinical trials.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Pharma collaboration(s) with AstraZeneca on FOCUS4</gtr:description><gtr:id>CEC8EA1D-C074-4A7D-93EF-B53F79607D5F</gtr:id><gtr:impact>none as yet</gtr:impact><gtr:outcomeId>fr32K5urgKt-1</gtr:outcomeId><gtr:partnerContribution>Provision of the agent and placebo as well as the mechanism of distribution to about 20 sites</gtr:partnerContribution><gtr:piContribution>The FOCUS4 trial as a framework for studying the effect of AZD8931 in all-wild-type (non-mutated) colorectal cancer. In 2016, this will be expanded to include the testing of AZ's WEE1 inhibitor in various marker cohorts expected to be vulnerable to a mechanism of synthetic lethality.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Oncology</gtr:department><gtr:description>Collaboration with AstraZenca</gtr:description><gtr:id>CC23F751-74D9-4BD3-BD3F-35AD70A9312F</gtr:id><gtr:impact>For MRC CTU, the provision of this agent has helped get the FOCUS4 trial launched quickly. For AstraZeneca, this is an important test of an agent that otherwise might not have a pathway to market.</gtr:impact><gtr:outcomeId>PJBsVVPyNnq-1</gtr:outcomeId><gtr:partnerContribution>Extensive discussion by company and MRC teams of the agent's mechanism of action and safety in preparation for its selection for FOCUS4</gtr:partnerContribution><gtr:piContribution>Agreement to collaboratively explore a new agent (AZD8931) in colorectal cancer, in the FOCUS4 trial</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>F. Hoffmann-La Roche AG</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:department>Roche Diagnostics</gtr:department><gtr:description>Colorectal Trials - Roche</gtr:description><gtr:id>20CC278B-472A-44D6-9914-2546709BAC75</gtr:id><gtr:impact>Th e FOCUS3 trial has completed accrual. A manuscript is being prepared.</gtr:impact><gtr:outcomeId>ctnusozPVap-1</gtr:outcomeId><gtr:partnerContribution>Roche are providing financial support for the MRC Colorectal Porgramme.</gtr:partnerContribution><gtr:piContribution>Roche are collaborating with the MRC colorectal team on the MRC FOCUS3 trial which is co-ordinated by the MRC CTU</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bayer</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Bayer HealthCare</gtr:department><gtr:description>Add-Aspirin trial - Bayer Pharmaceuticals PLC</gtr:description><gtr:id>3C99B263-DF95-41B1-915F-83F1E7824C98</gtr:id><gtr:impact>Contract signed, no output to date. The trial is currently in set-up.</gtr:impact><gtr:outcomeId>5459faf5da2257.86001473-1</gtr:outcomeId><gtr:partnerContribution>Bayer Pharmaceuticals are supplying the Add-Aspirin trial medication (100mg aspirin tablets, 300mg aspirin tablets and matched placebos) free of charge.</gtr:partnerContribution><gtr:piContribution>We approached Bayer to supply the drugs for the Add-Aspirin trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sanofi</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Aventis</gtr:department><gtr:description>FOCUS Sanofi-Synthalebo Collaboration</gtr:description><gtr:id>AC71B0D7-3C8D-4E0A-B88D-95C484B8EAAA</gtr:id><gtr:impact>Results from the MRC FOCUS trial have been presented at national and international scientific meetings. Primary trial publication: 17630037</gtr:impact><gtr:outcomeId>B91FB74AC20-1</gtr:outcomeId><gtr:partnerContribution>Sanofi-Synthelabo provided free oxaliplatin for patients in Arm E of the MRC FOCUS trial</gtr:partnerContribution><gtr:piContribution>MRC CTU have been responsible for the design, co-ordination, management and analysis of the MRC FOCUS trial.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>S-CORT MRC-CRUK Consortium</gtr:description><gtr:id>22F27480-BD1C-4F15-9653-029E3475BCE7</gtr:id><gtr:impact>Some preliminary publications, but main outputs are yet to come</gtr:impact><gtr:outcomeId>56dc26f83d1999.27596844-2</gtr:outcomeId><gtr:partnerContribution>The development of a portal for entry and curation of large scale biological data (Oxford); the performance of translational laboratory studies (all the other partners)</gtr:partnerContribution><gtr:piContribution>We serve as the central link between the clinical and outcome data of thousands of patients, access to their tumour and blood samples, and the data from an array of translational laboratory studies carried out by the consortium as a whole. We also provide statistical design advice.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Colorectal Trials - University of Cardiff</gtr:description><gtr:id>4B5DD39D-BB9B-4C24-AB86-B5D1FEEB2868</gtr:id><gtr:impact>The translational research associated with the COIN, COIN-B and FOCUS3 trials is all currently ongoing or due to begin in 2010. Because of evidence that KRAS mutational status in patients' tumours is a key predictor of response to agents such as cetuximab the translational reesearch component of the trial was key to analysis of the trial's primary clinical outcome measure of overall survival in patients with KRAS wild-type colorectal cancer.</gtr:impact><gtr:outcomeId>F680C04626D-1</gtr:outcomeId><gtr:partnerContribution>The translational research components of the MRC COIN and COIN-B trials and part of the translational research component of the FOCUS-3 trial were carried out or are currently being carried out by research teams at the University of Cardiff</gtr:partnerContribution><gtr:piContribution>The colorectal team at the MRC CTU work closely with the translational research teams at the University of Cardiff to ensure the success of the translational studies attached to the colorectal clinical trials.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>S-CORT MRC-CRUK Consortium</gtr:description><gtr:id>C3513EC6-5448-46ED-B789-A14246E1C183</gtr:id><gtr:impact>Some preliminary publications, but main outputs are yet to come</gtr:impact><gtr:outcomeId>56dc26f83d1999.27596844-6</gtr:outcomeId><gtr:partnerContribution>The development of a portal for entry and curation of large scale biological data (Oxford); the performance of translational laboratory studies (all the other partners)</gtr:partnerContribution><gtr:piContribution>We serve as the central link between the clinical and outcome data of thousands of patients, access to their tumour and blood samples, and the data from an array of translational laboratory studies carried out by the consortium as a whole. We also provide statistical design advice.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Research Institute (NCRI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NCRI Colorectal Cancer CSG</gtr:department><gtr:description>Colorectal trials - NCRI Colorectal Clinical Studies Group</gtr:description><gtr:id>A4593CE6-1CF9-494D-9EC0-0F523CA36118</gtr:id><gtr:impact>Results from the MRC CR07 trial have been presented at national and international scientific meetings. Primary trial publications: 19269519 and 19269520 Results from the MRC FOCUS trial have been presented at national and international scientific meetings. Primary trial publication: 17630037 Results from the MRC FOCUS2 trial have been presented at national and international scientific meetings. A manuscript presenting the trial results is currently in preparation. The COIN trial recently completed accrual and the first results were presented at the ESMO/ECCO international congress in Sept 2009 and at the NCRI annual meeting in October 2009. Manuscripts describing the trials and the results are in preparation. One publication has also resulted from this trial to date: PMID 19165196. Main trial results have been submitted for publication in 3 manuscripts.</gtr:impact><gtr:outcomeId>F6DA8D4AF5E-1</gtr:outcomeId><gtr:partnerContribution>All of the MRC CTU colorectal trials are run in collaboration with the NCRI colorectal cancer CSG which as a group discusses trial design and encourages national participation in the trial</gtr:partnerContribution><gtr:piContribution>MRC CTU have been responsible for the design, co-ordination, management and analysis of the MRC CR07, FOCUS , FOCUS-2, COIN and COIN-B trials.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Baxter</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Baxter Healthcare</gtr:department><gtr:description>Colorectal Trials - Baxter Collaboration</gtr:description><gtr:id>1DE4EED7-8685-4B89-891C-108F33FA7D1F</gtr:id><gtr:impact>Results from the MRC FOCUS trial have been presented at national and international scientific meetings. Primary trial publication: 17630037 Results from the MRC FOCUS2 trial have been presented at national and international scientific meetings. A manuscript presenting the trial results is currently in preparation. The COIN trial recently completed accrual and the first results were presented at the ESMO/ECCO international congress in Sept 2009 and at the NCRI annual meeting in October 2009. Manuscripts describing the trials and the results are in preparation. One publication has also resulted from this trial to date: PMID 19165196</gtr:impact><gtr:outcomeId>7B4B1B00E28-1</gtr:outcomeId><gtr:partnerContribution>Baxter provided reduced price ambulatory pumps to FOCUS/FOCUS2/COIN/COINB trial sites for adminstration of trial chemotherapy.</gtr:partnerContribution><gtr:piContribution>MRC CTU have been responsible for the design, co-ordination, management and analysis of the MRC FOCUS , FOCUS-2, COIN and COIN-B trials.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sanofi</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Aventis</gtr:department><gtr:description>COIN Sanofi-Aventis Collaboration</gtr:description><gtr:id>8551CF61-10A2-4BAA-A03D-0B1A40E9FA44</gtr:id><gtr:impact>The COIN trial recently completed accrual and the first results were presented at the ESMO/ECCO international congress in Sept 2009 and at the NCRI annual meeting in October 2009. Manuscripts describing the trials and the results are in preparation. One publication has also resulted from this trial to date: PMID 19165196 Main trial results have been submitted for publication in 3 manuscripts.</gtr:impact><gtr:outcomeId>7CFB58C37BE-1</gtr:outcomeId><gtr:partnerContribution>Sanofi-Aventis provided free oxaliplatin for patients in Arm B of the COIN trial until oxaliplatin was approved for the treatment of patients with advanced colorectal cancer in the UK (NICE approval)</gtr:partnerContribution><gtr:piContribution>MRC CTU have been responsible for the design, co-ordination, management and analysis of the MRC COIN trial.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>S-CORT MRC-CRUK Consortium</gtr:description><gtr:id>BB20CF0E-D3CB-45AD-A382-41B99E4B66A7</gtr:id><gtr:impact>Some preliminary publications, but main outputs are yet to come</gtr:impact><gtr:outcomeId>56dc26f83d1999.27596844-1</gtr:outcomeId><gtr:partnerContribution>The development of a portal for entry and curation of large scale biological data (Oxford); the performance of translational laboratory studies (all the other partners)</gtr:partnerContribution><gtr:piContribution>We serve as the central link between the clinical and outcome data of thousands of patients, access to their tumour and blood samples, and the data from an array of translational laboratory studies carried out by the consortium as a whole. We also provide statistical design advice.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Wyeth Pharmaceuticals</gtr:department><gtr:description>Colorectal Trials - Wyeth Collaboration</gtr:description><gtr:id>20A5B583-2C55-4A70-B0CF-46D3647885D6</gtr:id><gtr:impact>Results from the MRC FOCUS trial have been presented at national and international scientific meetings. Primary trial publication: 17630037 Results from the MRC FOCUS2 trial have been presented at national and international scientific meetings. A manuscript presenting the trial results is currently in preparation. The COIN trial recently completed accrual and the first results were presented at the ESMO/ECCO international congress in Sept 2009 and at the NCRI annual meeting in October 2009. Manuscripts describing the trials and the results are in preparation. One publication has also resulted from this trial to date: PMID 19165196</gtr:impact><gtr:outcomeId>8C0B503DBD6-1</gtr:outcomeId><gtr:partnerContribution>Wyeth have produced reduced price L-folinic acid for use in the MRC FOCUS, FOCUS-2 and COIN trials</gtr:partnerContribution><gtr:piContribution>MRC CTU have been responsible for the design, co-ordination, management and analysis of the MRC FOCUS , FOCUS-2, COIN and COIN-B trials.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Almac Group</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ALMAC biomarker validation</gtr:description><gtr:id>7DF2F464-3DE4-4D4A-820E-DCF3B779F846</gtr:id><gtr:impact>analyses pending</gtr:impact><gtr:outcomeId>dPA3TdrYjCn-1</gtr:outcomeId><gtr:partnerContribution>In collaboration with funding from Merck, has made possible the assessment of role of EGFR ligands on outcome of COIN trial, and helps with planning of successor colorectal trials</gtr:partnerContribution><gtr:piContribution>COIN trial samples are being provided to ALMAC (under Merck funding) for measuring epiregulin, amphiregulin and other EGFR ligands, and other biomarkers, to confirm a possible role as predictive biomarkers for response to anti-EGFR antibodies</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Immatics Biotechnologies GmbH</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Colorectal Trials - Immatics</gtr:description><gtr:id>39C28A26-395B-4C7A-A026-EA185D650C0B</gtr:id><gtr:impact>No data has been published to date.</gtr:impact><gtr:outcomeId>m2aGrSChhiy-1</gtr:outcomeId><gtr:partnerContribution>Immatics are conducting a clinical trial, the primary objective of which is to determine whether IMA910 as single agent with GM-CSF as adjuvant following pre-treatment with low-dose cyclophosphamide is safe and shows sufficient anti-tumour effectiveness in patients with advanced CRC to warrant further development. Using the arm C data of the COIN trial for matched pair analysis with the data generated in the trial will allow a more solid and adequate assessment of effectiveness of IMA910 with respect to disease control rate and overall survival.</gtr:partnerContribution><gtr:piContribution>The MRC team have provided clinical data and tumour samples from patients randomised to Arm C of the MRC COIN trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Add-Aspirin Trial</gtr:description><gtr:id>ECE09D39-5BEA-4164-B853-113FDC690517</gtr:id><gtr:impact>trial in setup phase</gtr:impact><gtr:outcomeId>W6ggX9gRfo2-1</gtr:outcomeId><gtr:partnerContribution>funding from CRUK for Add-Aspirin Trial</gtr:partnerContribution><gtr:piContribution>application for Add-Aspirin trial funding</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Add-Aspirin trial launch meeting at NCRI conference Liverpool 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1893A6A6-1C4A-4B81-A1FE-B403DE6F1F72</gtr:id><gtr:impact>Add-Aspirin trial launch meeting- Trial promotion and training for research nurses and doctors hoping to participate in the trial at their site.

Increased requests for further information from sites interested in participating in the trial.</gtr:impact><gtr:outcomeId>545a094ba7c251.42319641</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Add-Aspirin oral presentation at ESMO world congress on Gastrointestinal Cancer Conference 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6B5B968C-D822-4110-A486-1C13B16F3A67</gtr:id><gtr:impact>Oral presentation and poster presentation entitled &amp;quot;Are the Benefits of Aspirin in Colorectal Cancer Limited to PIK3CA Mutated Cancers?&amp;quot; at an international conference. The talk promoted discussion and raised awareness of the Add-Aspirin trial.

Promoted discussion</gtr:impact><gtr:outcomeId>545a09e2748747.30924474</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://annonc.oxfordjournals.org/content/25/suppl_2/ii109.3.short</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>COIN Trial Results</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>6CA52FDB-45B5-4570-A396-D77BA27840A7</gtr:id><gtr:impact>A press release explaining the primary COIN trials results was released.

the story was picked up by a number of media sources.</gtr:impact><gtr:outcomeId>92DC9617CE1</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lay Summary of CR07 trial results</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>E21F8569-A467-40DA-A61A-3B021DFCFB33</gtr:id><gtr:impact>We have provided a lay summary of the CR07 trial results to all participating centres in the trial for dissemination to patients who participated in the trial.

Lay summary was only recently circulated but from experience reports like this are appreciated by patients.</gtr:impact><gtr:outcomeId>0E42B2C0E20</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>425908</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC FOCUS3</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0701770</gtr:fundingRef><gtr:id>6B509644-C74B-4677-9F67-8D31A978AB67</gtr:id><gtr:outcomeId>56dc3dce9cc5c8.75288138</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3124812</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Health Technology Assessment Programme (HTA)</gtr:department><gtr:description>NIHR (HTA) funding for Add-Aspirin trial</gtr:description><gtr:end>2023-04-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>12/01/38</gtr:fundingRef><gtr:id>1BAE7F85-FDFC-4A19-AD62-1196C13BF490</gtr:id><gtr:outcomeId>544fcf86459d90.16977900</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>403460</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK funding (CTAAC - FOCUS-2)</gtr:description><gtr:end>2006-08-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>9A2CBCB5-6B68-4AFA-9496-A57703FFA7B7</gtr:id><gtr:outcomeId>138EB7364A90</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3938399</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>FOCUS4 trial programme</gtr:description><gtr:end>2020-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>530551B4-888F-4AAC-BB40-B3FA07ACCF6E</gtr:id><gtr:outcomeId>T2D7pnhgmwF</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3598674</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Add-Aspirin trial - CRUK (CTAAC) grant</gtr:description><gtr:end>2023-12-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C471/A15015</gtr:fundingRef><gtr:id>8A2CFF63-FBFA-4C0C-8F9E-976642DD6F42</gtr:id><gtr:outcomeId>WGRpw13FQxQ</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3525623</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>FOCUS4 trial programme</gtr:description><gtr:end>2020-03-02</gtr:end><gtr:fundingOrg>NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC)</gtr:fundingOrg><gtr:fundingRef>11/100/50</gtr:fundingRef><gtr:id>4198102D-26D0-437C-BC8F-C3C8A1B04A93</gtr:id><gtr:outcomeId>56dc405d27f167.17499486</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>444766</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK funding (CTAAC-COIN)</gtr:description><gtr:end>2010-04-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>B855A938-18ED-42B7-8F5F-C14D32320E9B</gtr:id><gtr:outcomeId>E365523C49C0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>6137601</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>S-CORT MRC-CRUK consortium: Stratification in COloRectal cancer: from biology to Treatment prediction</gtr:description><gtr:end>2020-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/M016587/1</gtr:fundingRef><gtr:id>C2E6AEEF-39AB-4AD0-8DF7-DD48E3E7CBD5</gtr:id><gtr:outcomeId>56dc2830c2bf43.73310423</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>425892</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC IES Platform (FOCUS3)</gtr:description><gtr:end>2011-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>1727C9B3-A4AC-4BCB-B362-AA0D52029FFE</gtr:id><gtr:outcomeId>27E6C1C85FE0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>CR07 - RCPath Minimum Dataset</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>E60BF21E-DB98-41F1-A1F0-99D91FA77FF7</gtr:id><gtr:impact>Following on from the findings of the MRC CR07 trial the Plane of surgery is now a core item in the RCPath minimum dataset and is now a part of routine grading and reporting of rectal cancer surgery.</gtr:impact><gtr:outcomeId>382ACC2DC2E</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Colorectal Anti-EGFR SR (PMID:22118887) NCCN guideline 2015</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NCCN Guidelines Version 2.2015 Colon Cancer</gtr:guidelineTitle><gtr:id>3D6834FB-A848-4846-8937-517746F60080</gtr:id><gtr:impact>&amp;quot;A recent meta-analysis concluded there was a clear benefit to the use of EGFR inhibitors in patients with KRAS-wild-type metastatic colorectal cancer&amp;quot;, based on our systematic review and meta-analysis of summary data (PMID: 22118887)</gtr:impact><gtr:outcomeId>56ceef31d13473.75289411</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>intermittent chemotherapy as standard practice for first-line treatment of colorectal cancer</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E4C4A07A-A0DB-42F1-B53A-647B64A3DF81</gtr:id><gtr:impact>The MRC COIN trial confirmed in 2011 what data from the earlier MRC FOCUS trial had suggested, that for most patients having colorectal cancer chemotherapy, a break in the chemotherapy did not compromise survival. This approach began to be widely adopted as a standard in the UK even before completion of the COIN trial, which was very widely activated across the UK. This approach is now standard in the UK and influencing standards in other countries. It not only has quality of life and economic benefits but also serves as the platform for the next generation of chemotherapy trials.</gtr:impact><gtr:outcomeId>Z36eL1d5eT8</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>FOCUS data: NICE Technology Assessment TA93</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>29252FB1-73F6-4730-999D-7ACD9A20874C</gtr:id><gtr:impact>FOCUS data was submitted to NICE for use in their apparisal of the use of irinotecan and oxaliplatin for the treatment of advanced colorectal cancer. NICE made the following recommendation: Irinotecan and oxaliplatin, within their licensed indications, are recommended as treatment options for people with advanced colorectal cancer as follows: ? irinotecan in combination with 5-fluorouracil and folinic acid as first-line therapy, or irinotecan alone in subsequent therapy ? oxaliplatin in combination with 5-fluorouracil and folinic acid as first-line or subsequent therapy.</gtr:impact><gtr:outcomeId>826408936B9</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lack of benefit of cetuximab therapy in first-line treatment of colorectal cancer</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>80A90A61-38B3-4ADD-A572-A77B4A4E7C7B</gtr:id><gtr:impact>The COIN trial demonstrated that anti-EGFR antibody therapy with cetuximab does not improve progression-free survival outcome along with initial chemotherapy, even within the presumed most responsive subset of patients.</gtr:impact><gtr:outcomeId>aXHSiGttQNb</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS 3): A paradigm for randomised controlled trials in the era of personalised medicine?</gtr:description><gtr:id>A1AFC1DA-9552-4368-BDCA-35B96B1BB564</gtr:id><gtr:impact>The FOCUS 3 trial was a feasibility study designed to address the challenges of patient acceptability, technical logistics, and to test a novel design for examining the predictive role of biomarkers for 1st-line therapy of ACRC. We have shown that such studies are feasible and very well received by particpants. The central trial design concepts have been taken forward into a major UK trial programme FOCUS4 - molecular selection of therapy in CRC: a molecularly stratified RCT programme which will be launched in 2013.</gtr:impact><gtr:outcomeId>o1NKpXQ9WEy</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>FOCUS3</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://www.ctu.mrc.ac.uk/research_areas/study_details.aspx?s=52</gtr:url><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Cetuximab is a monoclonal antibody that is licensed in colorectal cancer, but the COIN trial demonstrated that its addition to 1st-line FOLFOX chemotherapy did not extend survival, even in patients without KRAS mutations. As the COIN trial participation was very broad among UK oncologists, this observation will prevent unnecessary toxicity and reduce costs throughout the country. Funding from Cancer Research UK, MRC and Merck-Serono</gtr:description><gtr:id>0DC48C23-D3B5-4E58-8A67-E4D952B82138</gtr:id><gtr:impact>The COIN trial assists in rationalising the use of an important but expensive cancer treatment.</gtr:impact><gtr:outcomeId>cMGRdYX6Fxx</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>COIN: Demonstration that cetuximab therapy does not improve outcome in combination with 1st-line chemotherapy for colorectal cancer</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=1314</gtr:url><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>The COIN trial established the use of intermittent chemotherapy, incorporating treatment breaks, as non-inferior standard treatment for colorectal cancer, except for patients with elevated platelet counts. Funding from Cancer Research UK, MRC and Merck-Serono.</gtr:description><gtr:id>8F88FB18-05D3-40F9-9796-9F70A3DAFE88</gtr:id><gtr:impact>Intermittent, rather than continuous chemotherapy for colorectal cancer has been studied for some years, including in earlier MRC trials in this programme, but the COIN trial developed large scale evidence for this approach. Also, the COIN trial was so widely supported across the UK that intermittent therapy has become a new and widely adopted standard of care. This approach saves toxicity for patients and chemotherapy expense for the NHS.</gtr:impact><gtr:outcomeId>F7PhKd38CPP</gtr:outcomeId><gtr:stage>Wide-scale adoption</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>COIN: Established intermittent chemotherapy as standard practice for first line colorectal cancer</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>ISRCTN 27286448</gtr:ukcrnIsctnId><gtr:url>http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=1314</gtr:url><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>FOCUS4 - Molecular selection of therapy in colorectal cancer: a molecularly-stratified randomised controlled trial programme.</gtr:description><gtr:id>41AFE887-14D1-4309-A59D-AD5487063A84</gtr:id><gtr:impact>A new trial design using stratified medicine and adaptive methods to test novel agents in colorectal cancer.</gtr:impact><gtr:outcomeId>LNRvxfMeztV</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>FOCUS4</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://www.controlled-trials.com/ISRCTN90061546/</gtr:url><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Add-Aspirin is a phase III, double-blind, placebo-controlled randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. It is currently in the set-up phase and funding has been secured from CRUK. Further funding applications are ongoing.</gtr:description><gtr:id>6B7668ED-542E-40F9-9085-18E7FCBDD52A</gtr:id><gtr:impact>under development. 
Novel methodology proposed including 4 individually powered trials integrated into one over-arching trial</gtr:impact><gtr:outcomeId>hH1QUrY1td1</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Add-Aspirin</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>MRC COIN-B is an open-label, multi-centre, randomised, 2-arm, phase II trial of how Cetuximab might safely and effectively be added to an intermittent chemotherapy (ICT) maintenance strategy, in the first-line treatment of advanced colorectal cancer (ACRC).</gtr:description><gtr:id>48EE24EE-7F23-41B4-B24C-2CF3EA7D0DE2</gtr:id><gtr:impact>In COIN-B, cetuximab was safely incorporated in two planned novel first line ICT strategies. Cetuximab maintenance was associated with a longer CFI and longer time to progression/death. This promising strategy of biological maintenance monotherapy in molecularly selected cohorts needs validation in phase III trials.</gtr:impact><gtr:outcomeId>abuvzkzLGJJ</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>COIN-B</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://www.ctu.mrc.ac.uk/research_areas/study_details.aspx?s=11</gtr:url><gtr:yearDevCompleted>2007</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>A secure database with built in checks/validations, as well as functionality for producing reports, has been developed in-house to record all data collected in the trial.</gtr:description><gtr:id>097E6227-7FAD-4503-B4DB-D00967A21A34</gtr:id><gtr:impact>Due to the size and scope of the planned trial (;10,000 participants with four different tumour types), the database is expected to provide a rich resource of information for use in future research beyond the original trial question. The data will be made available to other researchers via an application process.</gtr:impact><gtr:outcomeId>5459ffa8639734.96402979</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Add-Aspirin trial database</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>A stored collection of specimens (tumour and blood) from patients on a series of colorectal cancer therapeutic trials including FOCUS, FOCUS2, COIN, FOCUS3 and FOCUS4, along with anonymised demographic and outcome data</gtr:description><gtr:id>4FB356C8-7073-4F5B-B597-DB6F61D3D645</gtr:id><gtr:impact>At least 20 translational projects underway and many exploratory or pilot projects.
Publications listed as specific outputs.</gtr:impact><gtr:outcomeId>56dc43804c9094.80678796</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Colorectal trial specimen collection and outcomes database</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A new clinical trials design intended to be much more efficient than most trials in stratified medicine have been thus far</gtr:description><gtr:id>CFB7099E-C3CA-406E-8311-762DC97F399A</gtr:id><gtr:impact>Other trials actively being developed, using this design</gtr:impact><gtr:outcomeId>546202b06dd359.11239362</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>New trial design for stratified medicine clinical trials</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:url>http://jco.ascopubs.org/content/31/36/4562.full?sid=64cfcd5a-26c6-4690-bf24-e36aaf012852</gtr:url><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Formalin-fixed paraffin-embedded blocks of tumour and normal tissue from patients in the MRC FOCUS (approx. 1600 patient samples), FOCUS-2 (approx. 400 patient samples), COIN (approx. 2100 patient samples), COIN-B (approx. 200 samples) and FOCUS 3 (200 samples) trials have been collected and banked at the University of Leeds and the Wales Cancer Bank. In addition samples of whole blood have also been collected from patients participating in the FOCUS-2, COIN and COIN-B trials.</gtr:description><gtr:id>55128BC7-5035-46A4-B606-46F167899DDD</gtr:id><gtr:impact>The number of research projects carried out using these samples is now more than 25, with results from several of these translational studies presented at national and international scientific meetings and published (PMID references: 18509181, 19884549, 19858398, 22118887, 22634755) . KRAS mutational status (obtained from testing tumour tissue) ended up being a key componenet of the primary analysis of the COIN trial results and a feature of the design of the FOCUS4 trial programme.</gtr:impact><gtr:outcomeId>6B8CE305C00</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Colorectal Trials: Tumour Samples for Translational Research</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:url>http://europepmc.org/abstract/MED/18509181</gtr:url><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A pooled set of specimens plus complete corresponding clinical data, including outcome data from a series of colorectal cancer trials</gtr:description><gtr:id>B4DE5D63-86FD-4E92-AAB8-208835C14C39</gtr:id><gtr:impact>Multiple use in piloting and quality assuring assays for biomarker and other translational studies, as well as serving as a resource for more definitive translational research</gtr:impact><gtr:outcomeId>56dee4535aa640.07828726</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Combined FOCUS, FOCUS2, COIN, FOCUS3, and FOCUS4 specimen collection</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>A drug supply management system tailored to the trial requirements has been developed in-house to provide a secure system for coordinating all aspects of the drug supply process in the study. The drug packaging and distribution team, as well as research staff and pharmacists at participating sites will have web-based access to the system, and it will allow close oversight of the whole process by the Trials Unit team. Input from all of the relevant parties has been sought in developing the system and it has been designed in such a way that it can subsequently be adapted for use in future trials conducted at the unit.</gtr:description><gtr:id>0288A9EF-57B0-42F0-8ABF-34A12A4B872E</gtr:id><gtr:impact>This in-house system may replace the need to out-source the management of drug supply processes, and so will have cost-saving implications both within Add-Aspirin and for future trials.</gtr:impact><gtr:outcomeId>545a000bf40ee7.93184997</gtr:outcomeId><gtr:title>Add-Aspirin Drug Supply Management System</gtr:title><gtr:type>Software</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>91FD7D46-55BD-4D04-A7F9-6ECB722D0172</gtr:id><gtr:title>Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f2468b3d4122a06144b1c4cb9552059"><gtr:id>6f2468b3d4122a06144b1c4cb9552059</gtr:id><gtr:otherNames>Adams RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>54620a29807370.35628439</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDD8481A-7FA1-4906-9283-E303F5A39A5D</gtr:id><gtr:title>Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f908ccb4a423a6ffd55c5b6b79b4361c"><gtr:id>f908ccb4a423a6ffd55c5b6b79b4361c</gtr:id><gtr:otherNames>Braun MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>C8D371E71F1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4FF9C28-EBB4-4C99-A69C-E4329969BDDF</gtr:id><gtr:title>The cost-effectiveness of different chemotherapy strategies for patients with poor prognosis advanced colorectal cancer (MRC FOCUS).</gtr:title><gtr:parentPublicationTitle>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f851eb34749a2d6d616b64b69a3d6825"><gtr:id>f851eb34749a2d6d616b64b69a3d6825</gtr:id><gtr:otherNames>Manca A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1098-3015</gtr:issn><gtr:outcomeId>doi_13787_011_07_008</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF053FC0-1B29-4B25-82BA-8A1F412764FB</gtr:id><gtr:title>Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dbe30c8eb6a4737672e1453b53d2be21"><gtr:id>dbe30c8eb6a4737672e1453b53d2be21</gtr:id><gtr:otherNames>Grenader T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>58b99006d3eea1.59096385</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4365975-83AA-4A9B-9F02-7C3CF8CA08B0</gtr:id><gtr:title>Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/29f37f6d5dec386b00c54909a6fb8aa9"><gtr:id>29f37f6d5dec386b00c54909a6fb8aa9</gtr:id><gtr:otherNames>Dunlop MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>pm_13787_27_22634755</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9B997CD-1E8B-4CF3-ACE9-35897EFAB100</gtr:id><gtr:title>Clinical evidence for the use of aspirin in the treatment of cancer.</gtr:title><gtr:parentPublicationTitle>Ecancermedicalscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a71af17ab23169ccaa01135ba3297c2"><gtr:id>2a71af17ab23169ccaa01135ba3297c2</gtr:id><gtr:otherNames>Langley RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1754-6605</gtr:issn><gtr:outcomeId>pm_13787_27_23589726</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31821470-CE2A-44B0-A864-0BB02A892FEE</gtr:id><gtr:title>Exome resequencing identifies potential tumor-suppressor genes that predispose to colorectal cancer.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01d90d156377cc852ce598887481ab20"><gtr:id>01d90d156377cc852ce598887481ab20</gtr:id><gtr:otherNames>Smith CG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>pm_15667_27_23585368</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>33A5E9B8-6621-4D26-81B7-795032B66A73</gtr:id><gtr:title>Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45f370758702188a47f5cbc6020a1f31"><gtr:id>45f370758702188a47f5cbc6020a1f31</gtr:id><gtr:otherNames>Sebag-Montefiore D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>D939B755342</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4ABE1FD8-95C8-47D8-BC71-7FA213171E7C</gtr:id><gtr:title>Common genetic variation and survival after colorectal cancer diagnosis: a genome-wide analysis.</gtr:title><gtr:parentPublicationTitle>Carcinogenesis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc8d4669ee974944842d57b63d047f75"><gtr:id>cc8d4669ee974944842d57b63d047f75</gtr:id><gtr:otherNames>Phipps AI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0143-3334</gtr:issn><gtr:outcomeId>56c49efc944933.04740717</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BA0308E-27B7-46A9-B395-AD4CF270AF38</gtr:id><gtr:title>Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01d90d156377cc852ce598887481ab20"><gtr:id>01d90d156377cc852ce598887481ab20</gtr:id><gtr:otherNames>Smith CG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>56c49d7014a836.90720651</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D01B3DEA-7617-448C-9D08-D52706E150C2</gtr:id><gtr:title>A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08de9b7f92a6e1bce87ca67f1f46e310"><gtr:id>08de9b7f92a6e1bce87ca67f1f46e310</gtr:id><gtr:otherNames>Al-Tassan NA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56c49efcb99146.28706828</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7E52837-FE7D-4BDE-8A80-919C80DFB66C</gtr:id><gtr:title>Changing the Paradigm-Multistage Multiarm Randomized Trials and Stratified Cancer Medicine.</gtr:title><gtr:parentPublicationTitle>The oncologist</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6102ec8bfcb4cfb87cb034e8c4067870"><gtr:id>6102ec8bfcb4cfb87cb034e8c4067870</gtr:id><gtr:otherNames>Lawler M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1083-7159</gtr:issn><gtr:outcomeId>56c49d70e64848.76086201</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0134AE56-9691-4143-B711-C635FCEA5271</gtr:id><gtr:title>Aspirin in gastrointestinal oncology: new data on an old friend.</gtr:title><gtr:parentPublicationTitle>Current opinion in oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a71af17ab23169ccaa01135ba3297c2"><gtr:id>2a71af17ab23169ccaa01135ba3297c2</gtr:id><gtr:otherNames>Langley RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1040-8746</gtr:issn><gtr:outcomeId>56e011023d27a4.26298401</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30A3E289-D084-4D7F-BE44-C5E89AA426F9</gtr:id><gtr:title>A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e96a47f840e64fa213f5d842daf1e753"><gtr:id>e96a47f840e64fa213f5d842daf1e753</gtr:id><gtr:otherNames>Maughan TS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>5461fc538e9415.93615826</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8047DAD-387F-4BCC-A0BA-66E085FE46EC</gtr:id><gtr:title>Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11b60f660066e306ba7823f7c9fe1777"><gtr:id>11b60f660066e306ba7823f7c9fe1777</gtr:id><gtr:otherNames>Venderbosch S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>56c49d6fd11961.59332839</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E84FD466-D1EC-4FA8-99DB-2DD9A5AE45BD</gtr:id><gtr:title>Evaluating many treatments and biomarkers in oncology: a new design.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/723c80601d0630665bb715ff60df02b8"><gtr:id>723c80601d0630665bb715ff60df02b8</gtr:id><gtr:otherNames>Kaplan R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>XRLhmKwv2rf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4B90408-64F9-4E2B-9811-3461C9953CF1</gtr:id><gtr:title>Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>Cancer treatment reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21f668352004702303f2e8e0e2b26d93"><gtr:id>21f668352004702303f2e8e0e2b26d93</gtr:id><gtr:otherNames>Vale CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0305-7372</gtr:issn><gtr:outcomeId>pm_13787_27_22118887</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFBA124B-5DFE-4A89-A3EA-2D6E5C09B5FC</gtr:id><gtr:title>Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69a6aa6937408e27000b9250780aebcd"><gtr:id>69a6aa6937408e27000b9250780aebcd</gtr:id><gtr:otherNames>Seymour MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>3BC48A014D0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E01AAE70-4654-4DE5-9E32-F30F773F4D15</gtr:id><gtr:title>Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee47981b9ad529e2c2d3a0aa0cc0133b"><gtr:id>ee47981b9ad529e2c2d3a0aa0cc0133b</gtr:id><gtr:otherNames>Folprecht G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>54408AC05E8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A18B2A33-7B5A-46D3-AD8E-53B7A6ED4545</gtr:id><gtr:title>Aspirin as a treatment for cancer.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1f5fb90f064bddeb754617a9e415b43"><gtr:id>d1f5fb90f064bddeb754617a9e415b43</gtr:id><gtr:otherNames>Phillips I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>doi_13787_013_03_001</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>183891EF-8B8D-4AFF-ACAD-0B0E3A02FCF1</gtr:id><gtr:title>Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f2468b3d4122a06144b1c4cb9552059"><gtr:id>6f2468b3d4122a06144b1c4cb9552059</gtr:id><gtr:otherNames>Adams RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>5BA7213DC58</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30CB948B-2ED5-425A-B7C4-6403E8950589</gtr:id><gtr:title>Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f908ccb4a423a6ffd55c5b6b79b4361c"><gtr:id>f908ccb4a423a6ffd55c5b6b79b4361c</gtr:id><gtr:otherNames>Braun MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>6205F6FBD32</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88B0C7A8-FD91-4735-B289-1CC395BF7504</gtr:id><gtr:title>KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17663fbed9d26d7e3a275c2886a2394c"><gtr:id>17663fbed9d26d7e3a275c2886a2394c</gtr:id><gtr:otherNames>Richman SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>05083021473</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1ABA7611-8436-488B-ADB7-FE6424A6F8BD</gtr:id><gtr:title>Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5e4cc07e3e10fa556bcfa80f07b50ea"><gtr:id>f5e4cc07e3e10fa556bcfa80f07b50ea</gtr:id><gtr:otherNames>Houlston RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>pm_13787_27_20972440</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3EDECE32-BE8C-434F-B1D0-424625AC78C6</gtr:id><gtr:title>Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer.</gtr:title><gtr:parentPublicationTitle>JAMA internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/654210cd2a1d06231975d65575015468"><gtr:id>654210cd2a1d06231975d65575015468</gtr:id><gtr:otherNames>Reimers MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2168-6106</gtr:issn><gtr:outcomeId>544fbff59bf563.82451434</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>971B991E-A6F1-4CA6-A96F-A9484CD2D9AC</gtr:id><gtr:title>Potential biomarker for aspirin use in colorectal cancer therapy.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Clinical oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a71af17ab23169ccaa01135ba3297c2"><gtr:id>2a71af17ab23169ccaa01135ba3297c2</gtr:id><gtr:otherNames>Langley RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1759-4774</gtr:issn><gtr:outcomeId>doi_13787_c_2012_216</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53123A9B-B4F7-4E47-893C-9285F4701596</gtr:id><gtr:title>Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/389467ee5d05de38f630f75e34c03b60"><gtr:id>389467ee5d05de38f630f75e34c03b60</gtr:id><gtr:otherNames>Maughan T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>pm_13787_27_20439628</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61114AF2-2589-4681-ABC8-2CE654B0264E</gtr:id><gtr:title>The Aspirin Foundation Scientific Conference: the history, the present state and the future of aspirin prophylaxis.</gtr:title><gtr:parentPublicationTitle>Ecancermedicalscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76f55bf11bf9112330ef9840251dd7d0"><gtr:id>76f55bf11bf9112330ef9840251dd7d0</gtr:id><gtr:otherNames>Smith T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1754-6605</gtr:issn><gtr:outcomeId>544fc0b7e23d18.35657910</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C611B1C2-55BB-4AF0-A186-2845062101DA</gtr:id><gtr:title>Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e96a47f840e64fa213f5d842daf1e753"><gtr:id>e96a47f840e64fa213f5d842daf1e753</gtr:id><gtr:otherNames>Maughan TS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>54620a29583b43.31922688</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E39944D8-EF69-42C6-8263-15C15E76C7E4</gtr:id><gtr:title>Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy &amp;plusmn; cetuximab.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01d90d156377cc852ce598887481ab20"><gtr:id>01d90d156377cc852ce598887481ab20</gtr:id><gtr:otherNames>Smith CG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>pm_15667_27_23741067</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6DB4F399-77BE-4006-BC18-C13628D1AC7B</gtr:id><gtr:title>Role of the oxidative DNA damage repair gene OGG1 in colorectal tumorigenesis.</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01d90d156377cc852ce598887481ab20"><gtr:id>01d90d156377cc852ce598887481ab20</gtr:id><gtr:otherNames>Smith CG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0027-8874</gtr:issn><gtr:outcomeId>pm_15667_27_23852950</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC623C6B-288E-43AD-B5DA-56A6825DC8F0</gtr:id><gtr:title>Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial.</gtr:title><gtr:parentPublicationTitle>Journal of clinical pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17663fbed9d26d7e3a275c2886a2394c"><gtr:id>17663fbed9d26d7e3a275c2886a2394c</gtr:id><gtr:otherNames>Richman SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9746</gtr:issn><gtr:outcomeId>56e022f02d6350.95951410</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E1776D9F-69D1-4F3A-AD94-A40AC4D10B04</gtr:id><gtr:title>Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c39e0c16568e5af0ec6d35554a48ac0d"><gtr:id>c39e0c16568e5af0ec6d35554a48ac0d</gtr:id><gtr:otherNames>Lieu CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>5aa8fd6b81b6f5.25565408</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE2A0ABB-1588-45BA-8A68-5080237DEC1C</gtr:id><gtr:title>More multiarm randomised trials of superiority are needed.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/541a4254e1d3febac0196c37bb2533c3"><gtr:id>541a4254e1d3febac0196c37bb2533c3</gtr:id><gtr:otherNames>Parmar MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>56e022f1725e78.86314662</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A302675D-BE1C-49EE-9127-0D70076D884D</gtr:id><gtr:title>Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/279847a920203c7c5d060385a389bda3"><gtr:id>279847a920203c7c5d060385a389bda3</gtr:id><gtr:otherNames>Quirke P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>315ED83582F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3003A5EE-D43D-44E4-9C94-58F4BCACFFCA</gtr:id><gtr:title>Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb7b6926531d2216e86891660ee26e15"><gtr:id>bb7b6926531d2216e86891660ee26e15</gtr:id><gtr:otherNames>Madi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_13787_27_22935584</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AFFB090-185B-4353-88A3-B4ECFDAE5B12</gtr:id><gtr:title>andLocus-Specific Variants Have Different Outcomes on Survival to Colorectal Cancer.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/937f68dcff8d968aaae259fa88742113"><gtr:id>937f68dcff8d968aaae259fa88742113</gtr:id><gtr:otherNames>Summers MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>58b98d0c7cdfe1.75925212</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8306FFE6-9240-4549-971B-299E568B4B94</gtr:id><gtr:title>Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a71af17ab23169ccaa01135ba3297c2"><gtr:id>2a71af17ab23169ccaa01135ba3297c2</gtr:id><gtr:otherNames>Langley RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_13787_27_21847126</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F60E1EDF-FEE2-4097-AB36-A61949103C7D</gtr:id><gtr:title>Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ebb635b035bd0aa767da4ff36cce666"><gtr:id>7ebb635b035bd0aa767da4ff36cce666</gtr:id><gtr:otherNames>Sargent DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>C8BE64B7D92</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A8735CE-1382-49ED-88D2-D773F3CF8B00</gtr:id><gtr:title>Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acd1ec81851500ff77017b336a8cf7b5"><gtr:id>acd1ec81851500ff77017b336a8cf7b5</gtr:id><gtr:otherNames>Wasan H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>545b8912a20a32.29090280</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1CAC4315-F2A5-4822-8AE2-9B6700AB57C6</gtr:id><gtr:title>Mendelian randomisation analysis strongly implicates adiposity with risk of developing colorectal cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/967b878cddb0708dbfb2fe7be3830f4e"><gtr:id>967b878cddb0708dbfb2fe7be3830f4e</gtr:id><gtr:otherNames>Jarvis D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>58b98dd7b21a21.61813176</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BAAC294F-909B-4089-B93B-28488198F142</gtr:id><gtr:title>Variation at 2q35 (PNKD and TMBIM1) influences colorectal cancer risk and identifies a pleiotropic effect with inflammatory bowel disease.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d18f86bb840d3de500000b0dfb8b07da"><gtr:id>d18f86bb840d3de500000b0dfb8b07da</gtr:id><gtr:otherNames>Orlando G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>58b98fb8000ef8.76399205</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7C7266A-35FD-4277-80F5-9768C686CE6F</gtr:id><gtr:title>The FOCUS4 design for biomarker stratified trials.</gtr:title><gtr:parentPublicationTitle>Chinese clinical oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/723c80601d0630665bb715ff60df02b8"><gtr:id>723c80601d0630665bb715ff60df02b8</gtr:id><gtr:otherNames>Kaplan R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2304-3865</gtr:issn><gtr:outcomeId>56dc4a75d3a312.68136513</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U122861325</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>6FFAED28-939F-4795-9FD1-98511549B3B8</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>6.5  Radiotherapy</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>